Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European Initiative.

Fecha de publicación: 01/06/2024 Fecha Ahead of Print: 25/04/2024

Autores de IIS La Fe

Emilio Monte Boquet

Autor

Participantes ajenos a IIS La Fe

Verbinnen I
Parow D
Lacombe F
Pothecary A
van Kuijk AWR
Harrington L
Müllerová E
Pinter A
Erstling U
Tomasini A
Helliwell PS

Abstract

INTRODUCTION: Psoriatic arthritis (PsA) is a complex, progressive, and often debilitating disease. Despite recent advances in treatment, numerous unmet needs in patient care persist. Rheumacensus is a multistakeholder, pan-European initiative designed to identify ways to elevate the standard of care (SoC) and treatment ambition for patients with PsA, using the perspectives of three key stakeholder groups: patients, healthcare professionals (HCPs) and payors. METHODS: Rheumacensus followed three phases: an insights-gathering workshop to identify current unmet needs in PsA and an area of focus for the project, a modified Delphi process to gain consensus on improvements within the agreed area of focus, and a Consensus Council (CC) meeting which used consensus statements as inspiration to generate 'Calls to Action' (CTA)-practical measures which, if implemented, could elevate the SoC for patients with PsA. RESULTS: The Rheumacensus CC consisted of four patient representatives, four HCPs and four payors. All 12 members completed all three Delphi e-consultations. The shared area of focus that informed the Delphi process was "patient empowerment through education on the disease and treatment options available, to enable patient involvement in management". Four key themes emerged from the Delphi process: patient empowerment, patient knowledge and sources of education, patient-HCP consultations, and optimal initial treatment. Statements within these themes informed 12 overarching CTA, which focus on the need for a multistakeholder approach to implementing a paradigm shift towards patient-centred care and improved outcomes for patients with PsA. CONCLUSION: Rheumacensus has identified shortcomings in the current SoC for patients with PsA and provides a foundation for change through practical CTA. It is hoped that all stakeholders will now take practical steps towards implementing these CTA across Europe to elevate the SoC for patients with PsA.

Datos de la publicación

ISSN/ISSNe:: 2198-6576, 2198-6584
Tipo:: Article
Páginas:: 795-815
DOI:: 10.1007/s40744-024-00664-3
Factor de Impacto:: 1,076 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Verbinnen I:: Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, Leuven Brain Institute, University of Leuven, Leuven, Belgium
Monte-Boquet E:: Pharmacy Department, Drug Clinical Area, Hospital Universitari i Politècnic la Fe, Valencia, Spain
Parow D:: Formerly Department of Medicines, Therapeutic Appliances and Remedies, DAK-Gesundheit, Hamburg, Germany
Lacombe F:: Association France Spondyloarthrites, Tulle, France
Pothecary A:: Department of Rheumatology, Royal Cornwall Hospitals NHS Trust, Truro, UK
Harrington L:: Ogilvy Health, Oxford, UK
Müllerová E:: Revma Liga Ceská Republika, z.s., Prague, Czech Republic
Pinter A:: Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
Erstling U:: Fachverband Rheumatologische Fachassistenz e.V., Bergisch Gladbach, Germany
Tomasini A:: National Association of People with Rheumatological and Rare Diseases, APMARR, Lecce, Italy
Helliwell PS:: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK